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Leukaemia cells that are resistant to conventional therapies are thought to reside in protective
niches. Here, we describe light-inducible polymeric retinoic acid (RA)-containing nano-
particles (NPs) with the capacity to accumulate in the cytoplasm of leukaemia cells for
several days and release their RA payloads within a few minutes upon exposure to blue/UV
light. Compared to NPs that are not activated by light exposure, these NPs more efﬁciently
reduce the clonogenicity of bone marrow cancer cells from patients with acute myeloid
leukaemia (AML) and induce the differentiation of RA-low sensitive leukaemia cells.
Importantly, we show that leukaemia cells transfected with light-inducible NPs containing
RA can engraft into bone marrow in vivo in the proximity of other leukaemic cells, differentiate
upon exposure to blue light and release paracrine factors that modulate nearby cells. The NPs
described here offer a promising strategy for controlling distant cell populations and remotely
modulating leukaemic niches.
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T
he differentiation of leukaemia cells is a therapeutic
strategy often used in the clinic to eradicate blood cancers.
The concentration of the agent used for inducing
leukaemia cell differentiation and the spatio-temporal control of
its application are important variables for the success of this
therapeutic approach1. Induction of leukaemia cell differentiation
by RA is a therapeutic strategy that has been used with great
success in the treatment of acute promyelocytic leukaemia
(APL)2,3. RA activates nuclear RA receptors (RARs) that induce
cell growth arrest and differentiation4. Despite its clear
therapeutic efﬁcacy, approximately 25% of patients receiving
RA will develop serious complications, such as ‘differentiation
syndrome’5. Hence, there is a need for more effective
formulations to deliver RA into leukaemia cells while
preventing RA side effects. In addition, leukaemia cells resistant
to conventional therapies reside in microenvironmental niches in
the bone marrow that are difﬁcult to access by therapeutic
interventions6. New strategies are required to address these
problems.
Nanoparticles (NPs) that disassemble in response to light7–9
offer a promising approach for reducing the side effects of
conventional therapies and increasing access of therapeutic
agents to the target cells. Recently, light-inducible NPs have
been reported to target solid tumours due to their speciﬁc
accumulation in tumour vasculature after intravenous injection10.
However, such an approach is not applicable to leukaemia. The
hypotheses of the present work are: (i) light-inducible NPs
containing RA may be a more effective strategy for differentiating
leukaemia cells because they release high and more effective
concentrations of RA in a short period of time (within minutes)
after NP disassembly, and (ii) light-inducible NPs containing
RA accumulated in the cytoplasm of leukaemia cells may offer a
unique opportunity to remotely differentiate these cells in
leukaemic niches in the bone marrow, which in turn may
interfere with the differentiation proﬁle of leukaemia cells in a
paracrine manner.
Here, we describe light-inducible polymeric NPs containing
RA that effectively disassemble within cells after light activation.
These NPs accumulate in the cytoplasm of leukaemia cells for
more than 6 days. They are internalized primarily through a
clathrin-mediated mechanism and at minor extent by macro-
pinocytosis. They escape in few hours the endolysomal compart-
ment and accumulate in cell cytoplasm. We show that these NPs
are more efﬁcient and quicker at inducing transcription from the
RARE-luciferase locus than RA in solution. We further show that
these NPs can be activated to release RA in vivo in a highly
controlled manner. Finally, we demonstrate that leukaemia cells
transfected with these cells can home in the bone marrow in the
same niche as other leukaemia cells, differentiate after blue laser
activation and modulate the activity/phenotype of the resident
leukaemia cells.
Results
Photo-disassembly and release properties of light-inducible
NPs. To prepare light-inducible polymeric NPs, poly(ethyleneimine)
(PEI) was initially derivatized with 4,5-dimethoxy-2-nitrobenzyl
chloroformate (DMNC), a light-sensitive photochrome (Fig. 1a
and Supplementary Fig. 1). PEI was selected as the initial NP
block because it facilitates the cellular internalization of NPs and
their subsequent escape from endosomes11,12, while DMNC was
selected because it responds rapidly to light and its degradation
products are relatively non-cytotoxic13. PEI–DMNC was then
added to dextran sulfate (DS) to form NPs by electrostatic
(PEI:DS) and hydrophobic (DMNC:DMNC) interactions. To
stabilize the NP formulation, zinc sulfate was added12,14.
NPs with an average diameter of 108.1±9.9 nm and a zeta
potential of 27.4±1.6mV were obtained.
To demonstrate that the NP formulation could be photo-
disassembled, a suspension of NPs was exposed to UV light for
up to 10min. The number of NPs (as assessed by Kcps) decreased
to below half of the initial number after 1min of UV exposure,
conﬁrming NP disassembly (Fig. 1b). The disassembly was likely
due to a change in the NP’s hydrophilic/hydrophobic balance
after DMNC photo-cleavage. Importantly, a conventional
blue laser (405 nm, 80mW) (Supplementary Fig. 2B) or a blue
confocal laser (405 nm, 30mW) (Supplementary Fig. 2C) can
replace the UV light to induce the photo-disassembly of NPs. The
response of the NPs to a blue laser was mediated by DMNC
coupled to PEI, as NPs without DMNC did not respond to the
laser (Supplementary Fig. 2B). We further evaluated the feasibility
of triggering intracellular NP disassembly. For that purpose,
HUVECs were transfected with quantum dots 525-labelled NPs
for 4 h (Supplementary Fig. 2D), and a small region of the cell
housing NPs was excited by a blue laser (405 nm) under a
confocal microscope. Under these conditions, NP ﬂuorescence
increases compared to a reference region not excited with blue
laser. This increase is due to NP disassembly and a resultant
decrease in the quenching of the quantum dots immobilized in
the NPs. Overall, our results show that we can disassemble NPs
by light, either in vitro or within cells.
To evaluate the light-inducible polymeric NPs as a method for
the controlled release of RA, a solution of RA with PEI-DMNC
was assembled with DS in aqueous solution to form NPs
(RAþNPs). Under these conditions, the carboxyl groups of RA
tend to form electrostatic interactions with the amine groups of
PEI14. The resultant NP formulation contained approximately
150 mg of RA per mg of NP, an average diameter of 160 nm and a
zeta potential of 22mV. The release proﬁle of the NP formulation
containing [3H]RA was monitored by scintillation after NP
exposure to UV light or a blue laser for up to 10min (Fig. 1c).
Up to 50 ng of RA was released per mg of NP after 10min of
activation. In the absence of light, up to 10 ng of RA was released
per mg of NP after 8 days (Supplementary Fig. 3).
Internalization and intracellular trafﬁcking of RAþNPs. Next,
we asked whether leukaemia cells could uptake light-inducible
NPs. According to our dynamic laser scattering studies, RAþNPs
are positively charged when resuspended in different culture
media and relatively stable for at least 24 h (Supplementary
Fig. 4). RAþNPs had no substantial effect on leukaemia cell
metabolism, as evaluated by an ATP assay for concentrations up
to 20 mgml 1 (Supplementary Fig. 5A; in case of non-leukaemic
cells no cytotoxicity was observed for RAþNPs up to
10 mgml 1—Supplementary Fig. 6). Human bone marrow APL
NB4 cells and human myelomonoblastic U937 cells (expressing a
chimeric PLZF/RARa fusion protein15,16 and showing impaired
sensitivity to RA17,18) were exposed to NPs for 4 h, washed to
remove excess NPs not taken up by the cells, either exposed or
not to UV light for 10min, and ﬁnally cultured for an additional
20 h. Because the activation of RAþNPs by UV or blue light can
induce double-stranded DNA breaks, we evaluated the effect of
this radiation on the phosphorylation of histone H2A (gH2AX),
an early biomarker of DNA damage19. Our results indicate that
neither UV nor blue light exposure for 10min had a signiﬁcant
impact on DNA damage (Supplementary Fig. 5B and C).
The intracellular accumulation of RAþNPs was monitored by
ﬂow cytometry and inductively coupled plasma mass spectro-
metry (ICP-MS) (Supplementary Fig. 7). Our results show that
NP internalization peaked at 6 h (Supplementary Fig. 7A and B)
and the intracellular concentration was dependent on the initial
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Figure 1 | NP photo-disassembly and cellular interaction. (a) Schematic representation for the photo-disassembly of RAþNPs. (b) Size, zeta potential
and number of NPs (Kcps) of an aqueous suspension of light-activatable NPs (50 mgml 1) exposed to UV light (365 nm, 100W) for up to 10min. (c)
Release of [3H]-RA from light-activatable NPs (10mgml 1 in water) after exposure to UV or a blue laser (405 nm, 80mW). (d) Dilution of TRITC-labelled
RAþNPs during THP-1 cell culture as monitored by ﬂow cytometry. Percentages of positive cells were calculated using non-transfected cells as control. (e)
THP-1 and NB4 cells were transfected with RAþNPs in serum-free medium for 4 h. Left: the concentration of NPs in THP-1 and NB4 cells was monitored
over 6 days by ICP-MS using Zn levels in NP. The amount of Zn in the cells after transfection (4 h) was deﬁned as 100%. Right: cell doublings over 6 days
as assessed by cell counting. (f) Internalization mechanism of RAþNPs. Left: uptake of TRITC-labelled RAþNPs in U937 cells after silencing key regulators
of endocytosis with siRNAs. Right: schematic representation of NP internalization pathways. (g) Intracellular trafﬁcking of FITC-labelled RAþNPs. HUVEC
cells were stained with LysoTracker DND-99 to monitor NPs trafﬁcking through the endolysosomal compartment overtime. (h) Fluorescence of NPs in the
cytoplasm measured by confocal microscopy. Scale bar represents 10mm. In b,c,d,e,f results are expressed as mean±s.e.m., n¼ 3. In g,h, results are
expressed as mean±s.e.m., n¼ 5. In f, statistical analyses were performed between control and the remain experimental groups using a one-way Anova
followed by a Newman–Keuls post-test. *Po0.05, ***Po0.001, ****Po0.0001.
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NP loading (Supplementary Fig. 7C). No signiﬁcant differences
were observed in the internalization proﬁles between cells.
Importantly, 60–100% of the leukaemia cells retained NPs in
culture for at least 6 days, as conﬁrmed by ﬂow cytometry (Fig. 1d
and Supplementary Fig. 8). This corresponded to the retention of
25–50% of the initial mass of the NPs during 8–10 cell doublings,
as obtained by ICP-MS analyses (Fig. 1e). Altogether, NPs were
efﬁciently internalized by human leukaemia cells and accumu-
lated intracellularly for several days.
To identify the pathways of RAþNP internalization, U937 cells
were incubated in the presence of endocytosis chemical inhibitors
at non-cytotoxic concentrations. Fluorescent-labelled RAþNPs
were then added and the internalization monitored by ﬂow
cytometry. Whenever possible, molecules that enter by a speciﬁc
internalization pathway were used as positive controls to show
the efﬁcacy of our inhibitors (Supplementary Fig. 9A). Dynasore
treatment (clathrin-mediated endocytosis (CME) inhibitor)
reduced the uptake of RAþNPs by 90% compared to control
cells (Supplementary Fig. 9B). To further conﬁrm the endocytosis
mechanisms involved in RAþNP internalization, U937 cells were
transfected with siRNAs to downregulate key components of
different endocytosis pathways (Fig. 1f). We observed a B60%
and B70% reduction in NP uptake upon downregulation of
clathrin heavy chain (CLTC), and low-density lipoprotein
receptor (LDLR), respectively, conﬁrming a role for CME. The
knockdown of macropinocytosis regulators Rac1 and CTBP1 led
to aB40% andB50% decrease in RAþNPs uptake, respectively,
suggesting that macropinocytosis was also involved in RAþNP
internalization (Fig. 1f).
To elucidate the intracellular trafﬁcking of our NPs, we used
adherent cells (HUVECs) to allow for this characterization by
confocal microscopy. The intracellular trafﬁcking of our NPs was
assessed ﬁrst by performing a LysoTracker staining to see the
general distribution of FITC-labelled RAþNPs in the endolyso-
somal system. During the ﬁrst few hours, there was an increase in
the intracellular signal of FITC-labelled RAþNPs and a clear
drop in the intensity of LysoTracker, suggesting an increase in the
pH of the endolysosomal vesicles by the presence of intracellular
PEI (a strong base), as well as possible vesicle disruption, as the
FITC-labelled NP signal was increased in the cytoplasm
(Fig. 1g,h). At later time points (12 h) of incubation with FITC-
labelled NPs, the intensity of LysoTracker reached control levels,
suggesting that the endolysosomal system regained its normal
characteristics. Our results further show that most of the NPs
(B80% of NP ﬂuorescence) escape endolysosomes within a few
hours (Fig. 1h). At 6 h, most of the FITC-labelled NPs were
distributed throughout the cytoplasm (B80% of the ﬂuorescence)
(Fig. 1h), and those that accumulated in the endolysosomal
compartment were located in vesicles positive for Rab5 (early/late
endosomes) and Rab7 (endosome/lysosomes) (Supplementary
Fig. 10A and B). This is consistent with a rapid escape of the NPs
from endosomes after uptake by the cell, likely due to their
buffering capacity which gives rise to osmotic swelling and
endosome rupture12.
Next, we asked whether RAþNPs would be efﬂuxed by
leukaemia cells overtime. It is known that tumour cells express
high levels of P-glycoprotein (P-gp), a membrane transporter that
is responsible for the efﬂux of drugs20 and NPs21. Therefore, we
used ﬂow cytometry to study the effects of the P-gp antagonist,
verapamil21, on the intracellular accumulation of RAþNPs in
Zn-induced U937-B412 cells expressing P-gp (Supplementary
Fig. 11A). Our results show that the intracellular accumulation
of RAþNPs in U937 slightly decreases from 4 to 12 h
(Supplementary Fig. 11B), in contrast to the control, ultra-small
paramagnetic iron oxide. The intracellular accumulation of ultra-
small paramagnetic iron oxide was highly dependent on the
inhibition of P-gp (Supplementary Fig. 11C). Overall, our results
indicate that RAþNP endocytosis takes place primarily through a
clathrin-mediated mechanism and at minor extent by
macropinocytosis. It is likely that both endocytic pathways are
interconnected, as has been demonstrated recently for lipid
NPs21,22. Our results further show that the internalization of
RAþNPs occurs quickly, and within the ﬁrst 2 h, a signiﬁcant
percentage of NPs tend to escape the endolysosomal
compartment, while the ones that do not escape accumulate in
early/late endosomes.
In vitro differentiation of leukaemia cells with RAþNPs.
Previously, liposomes22 and block copolymer NPs23 have been
used for the release of RA in myeloid leukaemia cell lines.
However, no signiﬁcant differences were observed between
liposome/NP formulations and soluble RA in their capacity to
induce leukaemia cell differentiation. Therefore, we evaluated the
capacity of light-inducible RAþNPs to prompt the differentiation
of human CD34þ primary leukaemia cells isolated from the
bone marrow aspirates of acute myeloid leukaemia (AML)
patients, taken at diagnosis. We evaluated their clonogenic
potentials in short-term (blast colony-forming units, CFUs) and
long-term (long-term culture-initiating cell, LTC-IC) assays
following treatment with RA or RAþNPs (Fig. 2a). Our results
indicate that light-inducible RAþNPs were more effective than
soluble RA at decreasing the number of CFUs (Fig. 2b). Our
results further indicate that RAþNPs activated by light are more
effective in decreasing the number of CFUs (Fig. 2c) and LTC-ICs
(Fig. 2d) than non-activated RAþNPs. We extended the previous
studies to different leukaemia cell lines, including U937, NB4
and THP-1 (Fig. 2e,g and Supplementary Fig. 12B). The
differentiation process was monitored by the expression of
myeloid maturation marker CD11b, a protein involved in the
regulation of leukocyte adhesion and migration. For equivalent
concentrations of RA, U937 (Fig. 2e) or NB4 (Fig. 2g) cells treated
with RAþNPs more readily differentiated into myeloid cells than
cells treated with soluble RA, likely due to the higher efﬁciency of
the NPs to deliver RA intracellularly (Fig. 2j and Supplementary
Fig. 12A). The differences in the intracellular accumulation
of RA are likely explained by the differences in RA uptake
mechanism. The RA is a hydrophobic small molecule with
limited water solubility (63mg l 1 (ref. 24)) and thus in vivo, it is
transported by proteins called cellular retinoic acid-binding
proteins (CRABP) both in extracellular and intracellular
compartments25. The expression of CRABP is relatively low in
undifferentiated leukaemic cells26 and thus the transport of
soluble RA to inside of the cell might be limited. In contrast, the
transport of RAþNPs occurs by endocytosis which might
facilitate the intracellular accumulation of RA.
U937 (Fig. 2f) or NB4 (Fig. 2h) cells treated with light-activated
RAþNPs showed a higher capacity for myelocytic differentiation
than cells treated with non-activated RAþNPs. In the case of
NB4 cells, RA released from light-inducible RAþNPs promoted a
higher percentage of cells expressing CD13highCD11bþ and
CD13lowCD11bþ (Fig. 3a,b) than soluble RA. NB4 cells
differentiated by light-inducible RAþNPs have a different
morphology from undifferentiated cells, showing polylobular
nuclei, decreased nuclear:cytoplasmic ratios and decreased
cytoplasm staining, as characterized by a May-Grunwald Giemsa
staining (Fig. 3c). The efﬁciency of the RAþNPs in delivering RA
inside NB4 cells and inducing a RA-dependent signalling
pathway was also conﬁrmed by the use of an NB4-RARE reporter
cell line. The RA-dependent induction of a RARE element driving
the transcription of the ﬁreﬂy luciferase gene was used to evaluate
the kinetics of RA-induction using RAþNPs or RA in solution.
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Figure 2 | Effect of RAþNPs on human leukaemia cells. (a) Schematic representation of the methodology used. (b) Differentiation of CD34þ AML cells
isolated from the bone marrow aspirates of patients with AML cultured with light-activated RAþNPs or soluble RA. (c,d) Differentiation of CD34þ AML
cells with RAþNPs (10 mgml 1) or blank (RA-NPs) NPs (10mgml 1), exposed or not to UV light, by a CFU (c) or LTC-IC (d) assays. Results are expressed
as a mean percentage of control plates containing only AML cells. (e,f) Myelocytic differentiation of human Zn-induced U937-B412 cells cultured with
light-activated NPs or soluble RA at day 3 (e) or cultured with RAþNPs with or without light activation (f). (g,h) Myelocytic differentiation of human
NB4 cells cultured with light-activated NPs or soluble RA at day 3 (g) or cultured with RAþNPs with or without light activation for 1 or 3 days (h).
(i) Intracellular release of RA as evaluated by a RARE luciferase cell line. NB4-RARE cells were cultured with soluble RA (3 mg of RA per ml) for the entire
duration of the experiment, or light-activatable RAþNPs (5mgml 1; 0.6mg of RA per ml). Cells were exposed to NPs for 1 h, washed with PBS and
resuspended in cell media. Some samples were exposed to UV light for 5min. The cells were then cultured for 24 h before luciferase luminescence reading.
(j) [3H]-RA uptake by NB4 cells. NB4 cells were cultured with soluble [3H]-RA (0.3 and 3mgml 1) for the entire duration of the experiment, or light-
activatable [3H]-RAþNPs (1 and 10mgml 1) for 4 h and then the cells were washed and cultured in cell medium for additional 20/68 h before scintillation
counting. From b to j, results are expressed as mean±s.e.m. (n¼ 3). In c,d,f,h, statistical analyses were performed by an unpaired t-test while
in i were performed by one-way ANOVA followed by a Newman–Keuls post-test. *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001.
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Our results showed that RAþNPs were able to induce high
levels of luciferase activity shortly after light activation (Fig. 2i).
RAþNPs were more efﬁcient and quicker at inducing transcrip-
tion from the RARE-luciferase locus than RA in solution.
Next, we monitored the effects of soluble RA and RA released
from RAþNPs in the transcriptional regulation of 96 genes
involved in the differentiation program of NB4 and U937
cells27,28 (Supplementary Figs 13 and 14). In the case of NB4
cells, CD52, CDKN1A (also known as the p21 gene) and TNFa
are recognized as direct targets of RA27; CD52 and CDKN1A are
upregulated and TNFa is downregulated in response to RA. Our
results show that the upregulation of CDKN1A and CD52 mRNA
transcripts was signiﬁcantly higher in cells treated with RAþNPs
compared to those treated with soluble RA for 8 h and 24–48 h,
respectively (Supplementary Fig. 15). On the other hand, the
downregulation of TNFa occurred more slowly in cells treated
with RAþNPs than in those treated with soluble RA. Other
RA-responsive genes were also evaluated by qRT–PCR27,29.
The number of mRNA transcripts for IL-8 and Ly6E genes was
higher in cells treated with RAþNPs than in those treated with
soluble RA for 8–24 h and 24–48 h, respectively. In addition, the
number of mRNA transcripts for CCR2 and CEBPa genes was
lower in cells treated with RAþNPs than in those treated with
soluble RA for 8–48 h and 8 h, respectively. Importantly, no
signiﬁcant variation in mRNA transcripts for RARa, RARb and
RARg (Supplementary Figs 13 and 15) was found between all
experimental groups. Therefore, our results suggest that the
differentiation proﬁle induced by RAþNPs is similar to that
observed for soluble RA; however, the magnitude of the effect in
the initial stages (up to 24 h) is higher in cells treated with
RAþNPs.
Recent studies report that lipid-based NPs are able to release
siRNA cargo in the cytosol only during a limited window of time,
when the NPs reside in a speciﬁc compartment that shares
early and late endosomal characteristics30,31. Therefore, we
evaluated the impact of temporal activation of RAþNPs on the
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differentiation of NB4 and U937 cells. The effect of the
intracellular release of RA was evaluated in terms of cell
differentiation into the myeloid lineage (expression of CD11b at
day 3) (Supplementary Fig. 16A). Cells that were incubated with
RAþNPs for 4–8 h and subsequently activated by light showed
the highest differentiation into the myeloid lineage. Interestingly,
cells incubated with RAþNPs for 1 h showed an already high
level of differentiation, indicating that NP uptake is rapid and
their endosomal escape is efﬁcient. Then, we asked whether cells
exposed for the same time (4 h) to NPs but activated at different
times (up to 44 h) during the intracellular trafﬁcking of RAþNPs
would have differences in their differentiation pattern
(Supplementary Fig. 16B). Our results show that even after 44 h
following NP internalization, the NPs can be activated and the
resultant delivery of RA in the cytosol can be relatively efﬁcient.
Similar results were obtained when the effect of temporal
intracellular RA release was evaluated by the induction of the
NB4-RARE reporter cell line (Supplementary Fig. 16B). Overall,
these results show that the NPs can be accumulated in the
intracellular environment and activated after a few days, without
losing their capacity to promote cell differentiation. Importantly,
a single activation procedure seems to be sufﬁcient to activate
RA release from the NPs because no signiﬁcant increase in
efﬁciency was observed when multiple rounds of light activation
were performed (Supplementary Fig. 17).
In vivo differentiation of leukaemia cells with RAþNPs. Next,
we evaluated if RAþNPs can function in vivo. We investigated
whether leukaemic cells loaded with RAþNPs could be activated
in vivo after subcutaneous transplantation. We selected a Matrigel
plug subcutaneous model because we know what is the attenua-
tion of the blue laser through the murine skin (Supplementary
Fig. 18A) and we could easily remove the cells from the Matrigel
plug and evaluate their differentiation by ﬂow cytometry. Initially
we evaluated whether the in vivo environment could interfere
with the differentiation program of leukaemic cells after ex vivo
activation. Human NB4 cells were cultured with RAþNPs for 4 h,
washed and activated ex vivo by exposure to a 405 nm blue laser
(80mW) for 5min, embedded in Matrigel and then injected into
a cylindrical poly(dimethylsiloxane) (PDMS) construct that was
previously implanted subcutaneously in NOD/SCID recipients
(Fig. 4a). The PDMS cylinder was used to restrict cell position
inside the animal. After 5 days, human cells were isolated from
the implants and CD11b expression measured by ﬂow cytometry
(Fig. 4b). Consistent with our in vitro data, CD11b expression was
statistically higher in NB4 cells treated ex vivo with light-activated
RAþNPs than in cells treated with RAþNPs without light
activation (Fig. 4b). The experiment was repeated with in vivo
activation. One day after implantation, the recipients were
exposed to a 405 nm blue optical ﬁbre for 5min at the implant
site (Fig. 4c). After 3 days, the recipients were killed, the human
cells were isolated and CD11b expression was assessed. CD11b
expression was higher in NB4 cells from mice that had been
exposed to the blue laser, demonstrating that internalized RAþ
NPs can be activated to release RA in vivo in a highly controlled
manner (Fig. 4c).
Homing and differentiation of leukaemia cells with RAþNPs.
Leukaemia cells that resist therapy reside in microenvironmental
niches in the bone marrow that are difﬁcult to reach by con-
ventional therapy6. Therefore, we investigated whether leukaemia
cells transfected with RAþNPs could engraft into the bone
marrow and localize at nearby resident leukaemia cells. For this
purpose, we transplanted leukaemia cells into immunodeﬁcient
CB17-Prkdcscid/J (NOD/SCID) mice treated with anti-CD122 to
deplete innate immune cells (NS122). Green ﬂuorescent protein
(GFP)-labelled THP-1 cells, a human APL cell line (NB4 cells
were unable to engraft), were injected into sub-lethally irradiated
mice in the tail vein, followed by the injection of THP-1 cells
transfected with RAþNPs after 24 h (Fig. 5a). After 1–2 days,
animals were killed and the cells in the animal’s calvaria
(cranium) were characterized by ex vivo imaging (Fig. 5b). Both
cells (GFP-labelled and NP-labelled THP-1 cells) could engraft in
the bone marrow of the animals and were detected after 1 or 2
days. Therefore, NP-labelled THP-1 cells (delivery cells) could
enter into the same niche as the GFP-labelled cells (target cells)
(Fig. 5c).
Next, we investigated whether we could differentiate the
NP-labelled human THP-1 cells (delivery cells) at the bone
marrow niche (more speciﬁcally at the calvaria), and whether
they could modulate nearby cells (Fig. 6a). Blue laser attenuation
studies in the calvaria bone using a photometer showed an
attenuation ofE75% (Supplementary Fig. 18B). Human THP-1
cells transfected with RAþNPs were injected intravenously into
CB17-Prkdcscid/J (NOD/SCID) mice, and 6 days after injection,
the cranium was exposed to a blue laser for 5min. Seventy-two
hours after blue laser irradiation, the engraftment of human
CD45þ cells in the long bones of non-irradiated and blue laser-
irradiated mice was 47.7±13.0 and 39.8±3.5%, respectively
(Fig. 6b). No statistical difference was found for the engraftment
in both groups. Ex vivo staining of mice calvaria showed that
human CD45þ cells in the non-irradiated mice did not express
CD11b, while B80% of the human CD45þ cells in blue-
irradiated mice expressed CD11b (Fig. 6c–e). In addition, cells
surrounding CD45þCD11bþ cells in irradiated mice expressed
CRABP, a RA protein transporter, while negligible levels of
CRABP were found in non-irradiated mice (Fig. 6f). Therefore,
THP-1 cells differentiated by a blue laser had the capacity to
modulate the cells in the vicinity. This is likely due to RA secreted
(including exosomes containing RA) by the THP-1 cells, as
observed in vitro using the NB4 cell line (Supplementary Fig. 19).
Overall, our results show that leukaemia cells transfected with
RAþNPs could (i) engraft into the bone marrow and localize
near to resident leukaemia cells, (ii) differentiate after blue laser
activation and (iii) modulate the activity/phenotype of the
resident leukaemia cells. It is possible that the cells that reach
the bone marrow are the ones that are less affected by the passive
diffusion of RA (that is, RA release without light activation)
within the cells. Therefore, the cells that engraft are likely the ones
that have less leaky RAþNPs and thus are undifferentiated
leukaemic cells (CD11bnegative phenotype).
Discussion. In conclusion, we have developed a light-inducible
polymeric NP for the spatio-temporal release of RA within leu-
kaemia cells. We showed the efﬁciency of RA release both in vitro
and in vivo. The efﬁciency is due to a combination of several
factors, including (i) high concentration of intracellular RA,
(ii) high endolysosomal escape (80% of the NPs escape the
endolysosomal compartment in the ﬁrst 5 h), (iii) prolonged
intracellular accumulation of the NPs (more than 6 days in
leukaemia cells) and (iv) rapid disassembly of the NPs once
activated by UV or blue light (within minutes). We further
showed that cells transfected with light-inducible NPs can be
activated after six days while maintaining the same inductive
properties. This gives an opportunity to use cells for activation at
speciﬁc sites in the human body and differentiate cells in their
proximity. Although the present study uses a RA delivery
system as a proof of concept, a similar approach could be
implemented for other drugs relevant to therapeutic or regen-
erative medicine.
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The present research reports a blue laser/UV-inducible NP.
The platform was designed for initial proof of concept regarding
the modulation of leukaemic cell niches in the bone marrow.
Recent studies have explored UV/blue laser approaches to trigger
in vivo the presentation of bioligands with spatial-temporal
control to regulate cell adhesion, inﬂammation and vasculariza-
tion of biomaterials32 and to detect protease activity at sites of
disease33. However, the in vivo applications of this light trigger
are limited, as the optical properties of biological tissue cause
attenuation and scattering of light rays, reducing their penetration
depth. The recent advances in developing NPs activated by near-
infrared light34 may provide a better option for enhancing light
penetration in tissues. For example, upconversion nanocrystals
that convert near infrared light into visible light (blue light) may
be an interesting possibility for the photo-cleavage of linkers to
which RA is chemically bound35.
We have used leukaemic cells as a programmable delivery
system that recognizes the leukaemic niches and modulate them
after light activation. The aim of the study was to show the
feasibility to remotely induce the differentiation of leukaemic cells
in the bone marrow and not to demonstrate the exhaustion of
cancer cells, as this will be difﬁcult using the blue laser activation
process. The concept here is different from previous studies that
have used therapeutic NPs coated with aptamers to direct them to
the bone marrow36. Although the results achieved are interesting,
the side effects of the systemic administration of the NPs
containing a powerful anti-leukaemic agent remain to be
determined. In the present study we have used cancer biology
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Figure 4 | In vivo differentiation of NB4 cells exposed to light-activatable RAþNPs. (a) Schematic representation of the in vivo experimental set up.
Cells were treated with blank or RAþNPs (both at 10 mgml 1) for 4 h, washed and then activated or not with a blue optical ﬁbre (405 nm, 80mW) for
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to ﬁght cancer. We have used leukaemia cells loaded with a
clinical-approved AML differentiating agent able to home to
leukaemic niches in the bone marrow. Although not explored in
the current study, normal hematopoietic stem cells may also
be used as a nanoparticle carrier as they are able to home to
leukaemic niches33.
Methods
Detailed methods are available in Supplementary Information.
Preparation and characterization of PEI conjugated with DMNC. DMNC
(48.5mg, Sigma) was slowly added to a solution of PEI in DMSO (2ml containing
50mgml 1 PEI, Sigma) containing triethylamine (24.5 ml, Sigma), and the reac-
tion ﬂask cooled to 0 C by immersion on ice. Then, the reaction was allowed to
proceed for 24 h at 25 C with stirring. At the end, the PEI-DMNC conjugate was
puriﬁed by dialysis (Spectra/Por 1 Regenerated Cellulose dialysis membrane,
MWCO 6000-8000Da, Spectrum) against DMSO overnight at room temperature.
Reaction yields above 54% were obtained. For NMR characterization, PEI-DMNC
(in DMSO) was precipitated in water, washed, freeze-dried and then dissolved
(10mgml 1) in DMSO-d6 and 1H NMR spectra were acquired using a Bruker
Avance III 400 MHz spectrometer.
Preparation of RAþNPs. For the preparation of RAþNPs, a RA solution
(24 ml, 50mgml 1, in DMSO) was added to a solution of PEI-DMNC (66.7ml,
150mgml 1 in DMSO) and maintained at room temperature for 30min, under
stirring. The solution was then carefully added to an aqueous solution of DS
(5ml, 0.4mgml 1) and stirred for 5min. The NPs in suspension were treated with
an aqueous solution of ZnSO4 (120 ml; 1M) for 30min. RA that was not encap-
sulated in the NPs was removed by centrifugation (12,000g for 3min). The NP
suspension was then dialysed (Spectra/Por 1 Regenerated Cellulose dialysis
membrane, MWCO 6,000–8,000Da, Spectrum) for 24 h, in the dark, against an
aqueous solution of mannitol (5%, w/v), lyophilized for 1 day and stored at 4 C
before use.
Cell culture. HUVECs (Lonza) were cultured in EGM-2 medium (Lonza) in a CO2
incubator at 37 C, 5% CO2 in a humidiﬁed atmosphere, with media changes
performed every other day. Cells were passaged every 2–5 days and used for
experiments between passages 4 and 6. Human bone marrow APL NB4 cells,
kindly provided by Dr Arthur Zelent (Institute of Cancer Research, Royal Cancer
Hospital), were cultured in RPMI-1640 (Gibco) supplemented with 10% fetal
bovine serum (FBS) (Gibco) and 100Uml 1 PenStrep (Lonza). Human myelo-
monoblastic cell lines U937-MT and U937-B412, kindly provided by Dr Estelle
Duprez (Centre de Recherche en Cance´rologie de Marseille, France), were main-
tained at exponential growth in RPMI-1640 medium supplemented with 10% FBS
and 100Uml 1 of PenStrep. For PLZF/RARA induction cells were stimulated
with 0.1mM ZnSO4 for at least 24 h. Human acute monocytic leukaemia cell line
THP-1 (DSMZ no. ACC16) was cultured in RPM1-1640 media supplemented with
HEPES (10mM), sodium pyruvate (1.0mM) and 2-mercaptoethanol (0.05mM).
NP internalization studies. NP internalization was monitored by ICP-MS. In this
case, the intracellular levels of Zn were measured before and after cell exposure to
NPs. NB4 and U937 cells (0.1 106 cells per well) were plated in 24-well plates and
incubated in serum-free RPMI-1640 from 1 to 24 h with variable amounts of
RAþNPs. After incubations, NPs that were not internalized by the cells were
washed (three times with PBS) and the cells were centrifuged; followed by the
addition of an aqueous solution of nitric acid (1ml, 69% (v/v)). The samples were
analysed by ICP-MS for the concentration of intracellular levels of Zn. The con-
centration of Zn was normalized per cell. The estimation of NPs was done based on
controlled standard solutions.
Mechanism of NP uptake. U937 cells were cultured on 24-well plates (1 105
cells per well) and inhibited by one of the following chemicals during 30min before
adding a suspension of TRITC-labelled NPs (5 mgml 1): EIPA (50 mM), dynasor
(80 mM), dansylcadaverine (100 mM), cytochalasin D (10 mM), nocodazole (50 mM),
ﬁlipin III (100 mM) and polyinosinic acid (100 mgml 1). The inhibitor con-
centrations were based in values reported in literature and further validated by us
to have no cytotoxic effect over the period of the assay (6 h), as conﬁrmed by an
ATP assay. The incubation of the cells with NPs for different times was performed
in the presence of the inhibitor. As controls, we used cells without NPs and cells
incubated with NPs without inhibitor. At the end of each time point, cells were
centrifuged at 1,300 r.p.m., 20 C for 5min with PBS, washed one time with cold
trypan blue solution (200ml; 600 mgml 1), re-washed three times with cold PBS
and then resuspended in PBS containing 2.5% FBS (500 ml) for ﬂow cytometry
analysis. A total of 10,000 events were obtained per measurement. To validate the
inhibitory activity of dynasor we performed uptake studies of FITC-labelled
transferrin, known to selectively enter cells via clatherin-mediated endocytosis.
Brieﬂy, U937 cells were cultured on 24-well plates (1 105 cells per well) and
treated or not with dynasor (80 mM, 30min pre-incubation), followed by addition
of 1 mgml 1 FITC-labelled transferrin (Life Technologies). The transferrin was
allowed to bind for 3min at 4 C. Cells were then evaluated as before.
The NP uptake mechanism was also studied on U937 cells by silencing speciﬁc
proteins of CME (CLTC and LDLR), caveolin-mediated endocytosis (CAV1),
GEEC-CCLIC pathways (CDC42) and macropinocytosis (RAC1 and CTBP1) by
siRNA (Thermo Fisher). Transfection was performed in a 24-well plate with
0.5 105 cells in antibiotic-free complete medium with 100 nM siRNA and 1.5 ml
of Lipofectamine RNAiMAX (Life Technologies) transfection reagent for 24 h.
After this initial period, the transfection medium was replaced by complete
medium and the cells incubated for another 48 h. Then, cells were cultured with
TRITC-labelled NPs (5mgml 1) for 6 h. Once the incubations were terminated,
the cells were centrifuged at 1,300 r.p.m., 20 C for 5min, with PBS, washed one
time with cold trypan blue solution (200 ml; 600mgml 1), re-washed three times
with cold PBS and then resuspended in PBS containing 2.5% FBS (500 ml) for ﬂow
cytometry analysis. Non-transfected cells or cells transfected with lipofectamine but
without siRNAs (MOCK) were used as controls. In all ﬂow cytometry analysis, a
total of 10,000 events were recorded per run. All conditions were performed in
triplicate.
Intracellular trafﬁcking analyses of NPs. HUVEC cells (passage 4) were cultured
on 1% gelatin-coated slides until subconﬂuency in EGM-2. The cells were then
incubated with FITC-labelled NPs (1mgml 1) for 1 or 4 h, washed extensively,
exposed or not to UV light (365 nm, 100W) and cultured in normal conditions for
up to 12 h. For LysoTracker staining, the cells were incubated with LysoTracker
Red DND-99 (50 nM, Invitrogen). After 30min of incubation, the coverslips were
washed extensively with PBS, followed by cell ﬁxation with paraformaldehyde
(4%, Electron Microscopy Sciences) for 10min at room temperature and then
washed with PBS. Cell nuclei were stained with 40,6-diamidino-2-phenylindole
(DAPI) (Sigma), and the slides were mounted with mounting medium (Dako)
and examined with a Zeiss LSM 50 confocal microscope.
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Figure 5 | Leukaemia cells transfected with RAþNPs can home at
leukaemia niches. (a) Schematic representation of the protocol. Human
GFP-labelled THP-1 cells were employed as the target cells and human
THP-1 cells without GFP label were employed as delivery cells. On day 0,
the target cells were injected into the NOD/SCID mice by intravenous
injection through the tail vein. On day 1, the delivery cells loaded with
RAþNPs were injected intravenously through the tail vein. After 24 (n¼ 3)
or 48 h (n¼ 3) of the delivery cell injection, the mice were killed, the
craniums collected and examined with a confocal microscope. (b) Both
target and delivery cells were observed in mice craniums at 24 and 48 h.
Bar scale means 100 mm. (c) Delivery cells close (o100mm) or distant
(4100 mm) to target cells were quantiﬁed. According to our results, the
delivery cells can enter into the same niche as the target cells. Results
are expressed as mean±s.e.m. (n¼ 3).
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NP dilution during cell proliferation. NP dilution with cell growth was monitored
over 6 days by ICP-MS by the quantiﬁcation of intracellular levels of Zn. NB4 and
THP-1 cells (0.5 106 cells per ml) were plated in six-well plates and incubated in
serum-free RPMI-1640 with 20 mgml 1 of RAþNPs. After 4 h incubation, NPs
that were not internalized by the cells were washed three times with PBS and the
cells were left to grow at 0.2 106 cells per ml in complete medium for additional
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4 h, 3 days and 6 days, maintaining always an exponential growth. After each
incubation, cells were counted, collected by centrifugation and resuspended in
nitric acid (1ml, 69% (v/v)) for ICP analysis. The concentration of Zn was nor-
malized per cell. The estimation of NPs was done based on Zn quantiﬁcation in
20mg of NPs. In some experiments, cells were transfected with RAþNPs labelled
with TRITC, and their ﬂuorescence monitored by ﬂow cytometry overtime, to
evaluate NPs distribution within the cells.
[3H]RA internalization studies. [11, 12-3H(N)]-Retinoic acid, 50.4 Cimmol 1,
was purchased from Perkin Elmer. [3H]RA solution for cell culture assays was
prepared on the day of experiments by dissolving [3H]RA in DMSO with unla-
belled RA in a 1:1,000 ratio to a ﬁnal concentration of 10 mM of RA. [3H]RA
solution in DMSO for the preparation of NPs was prepared on the day of
experiments using a 1:4,000 ratio of labelled to unlabelled RA. Experiments were
initiated by the adding the [3H]RA solution (1 mM and 10 mM; representing less
than 1% in volume of the total cell culture medium) or [3H]RA-NP suspension
(1mgml 1 and 10 mgml 1) to cultures (60,000 cells per condition, 24-well plate,
1ml) of NB4 or U937 cells. In case of soluble RA, cells (NB4 or U937; 60,000 cells
per condition, 24-well plate) were cultured with medium containing [3H]RA
(1mM and 10mM; 1ml of medium) for 24 or 72 h, washed with PBS (two times),
collected, lysed with lysis buffer (100ml) and kept on ice until scintillation
counting procedure. In case of RA-containing NPs, cells (same conditions as for
soluble RA) were cultured with [3H]RA-NPs (1 mgml 1 and 10 mgml 1) for 4 h,
washed with PBS and cultured for additional 20 or 68 h in the respective culture
medium. Cells were then collected to eppendorfs, washed with PBS, centrifuged
(1,500 r.p.m., 5min), lysed with lysis buffer (see above) and kept on ice until
scintillation counting procedure. The lysed samples (100ml) were mixed with
liquid scintillation ﬂuid (1ml; Packard Ultima Gold) and the scintillations counted
in a TriCarb 2900 TR Scintillation analyser (Perkin Elmer).
NB4 differentiation assay. Myelocytic differentiation of NB4 cells was assessed
by quantifying CD11bþ , CD11bþCD45þCD13high or CD11bþCD45þCD13low
populations using ﬂow cytometry. NB4 cells (between 6.0 104 and 10 104 cells
per condition) were plated in 24-well plates and cultured with soluble RA
(3mgml 1) or light-activatable RAþNPs (10 mgml 1) for 3 days. The NPs were
suspended in serum-free medium and added to cells for 4 h. The cells were then
washed by centrifugation (1,300 r.p.m., 5min) to remove non-internalized NPs,
and half of the samples were exposed to UV light (365 nm, 100W, 5min). The cells
were then cultured up to 3 days in RPMI-1640 medium supplemented with 10%
FBS and 100Uml 1 PenStrep with half medium changes every 3 days.
U937 differentiation assay. Myelocytic differentiation of U937 cells was assessed
by the quantiﬁcation of CD11b expression by ﬂow cytometry. U937-B412 cells
(6.0 104 cells per condition) were cultured either with or without ZnSO4
(0.1mM). To induce the expression of promyelocytic leukaemia zinc ﬁnger/RARa
(PLZF/RARa) in U937-B412 cells they were treated for 24 h with ZnSO4 (0.1mM).
Then cells were treated with soluble RA or light-activatable RAþNPs (transfection
for 4 h followed by light activation for 5min) for 3 days. After 1 and 3 days,
expression of CD11b on U937 cell surface was measured by staining with a
ﬂuorescent (PE)-conjugated anti-CD11b mAb (BD Biosciences) using ﬂow
cytometry.
AML differentiation assay. AML bone marrow mononuclear cells isolated by
Ficoll-Histopaque (GE Healthcare) gradient centrifugation, enriched using the
MACS CD34 isolation kit (Miltenyi Biotec) and cryopreserved were kindly pro-
vided by Dr Rajeev Gupta (Department of Haematology, UCL Cancer Institute).
The AML cells were isolated from an 85-year-old male patient with AML 34þ
117þ 33þ 13þDRþ 35% blasts and a 70-year-old woman with RAEB2/evolving
AML 34þ 117þ 33þ 12% blasts. Both samples had formal karyotyping/extended
FISH panels. Brieﬂy, neither patients were PML-RARA: one was standard risk
(normal karyotype with a small trisomy 8 subclone), and the other was high risk
with complex karyotype. The isolated CD34þ AML cells were maintained in
StemSpan SFEM medium (Stemcell Technologies) supplemented with a human
cytokine cocktail containing SCF (50 ngml 1, Stemcell Technologies), TPO
(15 ngml 1) and Flt-3L (50 ngml 1, PeproTech) plus PenStrep (10,000Uml 1,
Lonza) and Fungizone (25mgml 1, Sigma) up to 3 days. Prior to the colony-
forming cell (CFC) and LTC-IC assays, AML cells were incubated for 4 h in ex vivo
(Lonza) serum-free medium, with and without blank NPs or RAþNPs in a 24-well
plate. After that time, the cells were washed to remove loosely bound NPs. For CFC
assays (2.0 105 cells per condition), AML cells were plated in triplicate in
MethoCult H4230 medium (3ml, StemCell Technologies) supplemented with SCF
(50 ngml 1), IL-3 (10 ngml 1) and Flt-3L (50 ngml 1), all human, plus Pen-
Strep (10,000Uml 1, Lonza) and Fungizone (25 mgml 1, Sigma) in six-well plate.
In some conditions, RAþNPs accumulated within the cells were activated by a UV
light (365 nm, 100W, 5min). Cultures were scored after 14 days for the presence of
clusters and colonies containing 420 cells using an inverted microscope. LTC-IC
assays were performed in triplicate in a six-well plate gelatinized for 2 h before
adding the feeders. The feeder layer was composed of a 1:1 mixture of irradiated
(80Gy) SL/SL (1.5 104 cells per condition) and M210B4 mouse ﬁbroblasts
(1.5 104 cells per condition). AML cells (1 106 cells per condition) were plated
in Myelocult H5100 medium (StemCell Technologies), supplemented with Flt-3 L
(50 ngml 1), hydrocortisone (10 6 M) (StemCell Technologies) and PenStrep
(10,000Uml 1, Lonza) and fungizone (25mgml 1, Sigma). For some conditions
UV light (365 nm, 100W, 5min) was used to trigger RA release. After the cells
were inoculated, weekly half medium changes were performed (with Flt-3L
(100 ngml 1)) for the duration of the culture. After 5 weeks, all cells were col-
lected and placed into methylcellulose-based assay for the detection of AML-CFC
as described above.
Subcutaneous implantation in vivo. The animal work has been conducted
according to relevant national and international guidelines and approved by the
Bioethics Committee of University of Salamanca. On the day before injecting the
cells, PDMS cylindrical constructs (|internal¼ 1.0 cm; |external¼ 1.5 cm) were
implanted subcutaneously on NOD/SCID mice (Jackson Laboratory) maintained
in pathogen-free conditions with irradiated chow. For the ex-vivo activation studies
in the day of the experiment, NB4 cells were suspended in serum-free medium with
(i) no NPs, (ii) with empty NPs (10 mgml 1) or RAþNPs (10 mgml 1) for 4 h.
At the end, cells were washed by centrifugation (1,300 r.p.m., 5min), and the ones
treated with RAþNPs were either activated or not with a blue laser (405 nm,
80mW) for 5min. NB4 cells (5 106 cells per PDMS construct) were injected
subcutaneously in the centre of the PDMS construct embedded in Matrigel
(200 ml, BD Biosciences). Five days after injection of the cells, animals were killed
by cervical dislocation and cells within the cylindrical construct were collected and
characterized by ﬂow cytometry. For the in vivo activation studies in the day of the
experiment, NB4 cells were suspended in serum-free medium with (i) no NPs,
(ii) with RAþNPs (10 mgml 1) for 4 h. At the end, cells were washed by cen-
trifugation (1,300 r.p.m., 5min), and 5 106 NB4 cells per PDMS construct were
injected subcutaneously in the centre of the PDMS construct embedded in Matrigel
(200 ml). One day after injection, experimental groups were either activated or not
with a blue optical ﬁbre (405 nm, 80mW) for 5min. Three days after injection of
the cells, animals were killed by cervical dislocation and cells within the cylindrical
construct were collected and characterized by ﬂow cytometry.
Homing of leukaemia cells to leukaemic niches in vivo. NOD.CB17-Prkdcscid/J
(NOD/SCID) female mice, 6–8-week-old, received 1.5Gy of total body irradiation
from a 137Cs source and was treated with mouse anti-CD122 monoclonal antibody
(200 mg) by intraperitoneal injection. Human GFP-labelled THP-1 cells were
employed as the target cells and human THP-1 cells without GFP label were
employed as delivery cells. On day 0, the target cells (10,000,000 cells per mouse)
were injected into the NOD/SCID mice by intravenous injection through the tail
vein. On day 1, the delivery cells (10,000,000 cells per mouse; cells were suspended
in 200 ml of PBS) loaded with RAþNPs were injected intravenously through the tail
vein. The loading of the cells was performed as follows. Cells
were incubated for 4 h with TRITC-labelled RAþNPs (20 mgml 1) in RPMI
medium, washed with PBS to remove loosely bounded NPs, resuspended in
RPMI medium with 10% FBS for 18 h and then injected in the animals that had
received the target cells. After 24 (n¼ 3) or 48 h (n¼ 3) of the delivery cell
injection, the mice were killed, the craniums collected and examined with a
confocal microscope.
Bone marrow modulation in vivo. NOD.CB17-Prkdcscid/J (NOD/SCID) female
mice (n¼ 12) aged 6–8 weeks were employed in this experiment. Before cell
injection, mice received 1.5 Gy of total body irradiation from a 137Cs source and
were also treated with 200mg of mouse anti-CD122 monoclonal antibody (NS122)
by intraperitoneal injection. Human THP-1 cells were incubated with 20 mgml 1
of RAþNPs in RPMI medium for 4 h, followed by extensive wash with PBS to
remove non-internalized NPs. The cells were then resuspended in RPMI medium
with 10% FBS and left in the culture incubator overnight. On the following day, the
cells loaded with RAþNPs were collected and 1 107 cells per mouse in 200 ml
PBS were injected into the NOD/SCID mice intravenously, through the tail vein.
After 6 days, the mice were randomly divided into two groups: one of the groups
was blue laser irradiated (n¼ 6) and the other group was not irradiated (n¼ 6).
In the blue laser irradiated group, each mouse was anaesthetized with 3.5% chloral
hydrate in PBS and the craniums were exposed to a blue laser (405 nm, 80mW) for
5min. The mice in the non-irradiated group received the same treatment without
blue laser activation. After 48 or 72 h, the mice were killed and the long bones/
craniums were collected. The long bones including the femurs, tibias and pelvis
were crushed in PBS containing 1% bovine serum albumin (BSA, sigma) and
2mM EDTA (Invitrogen). The samples were then ﬁltered with 70 mm cell strainer
and treated with ACK solution to lyse red blood cells. The resulting cells were
stained using PE-conjugated anti-human CD45 antibody (eBioscience). The
results were measured by ﬂow cytometry and the data were analysed with FlowJo
software.
The mouse craniums were collected for the ex vivo staining examination
followed by the traditional protocol. Brieﬂy, the mouse craniums were cut into four
pieces along the sutures producing one frontal, two parietal and one occipital bone.
Only parietal bones were used in this experiment. Bone pieces were ﬁxed in 4%
paraformadehyde for 30min, washed twice with PBS, blocked with 2% BSA-0.01%
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Triton X-100 in PBS (BSA buffer) for 1 h, and incubated with primary antibodies
(diluted 1:100 in BSA buffer) overnight at 4 C. After washing with BSA buffer for
2 h, bones were incubated with secondary antibodies (diluted 1:200 in BSA buffer)
for 2 h, washed with BSA buffer for 2 h and nuclei were stained using DAPI.
The primary antibodies included mouse anti-human CD45 antibody (BD) and
rabbit anti- human CD11b antibody (Abcam). The secondary antibodies included
goat anti-mouse 555 (Invitrogen) and goat anti-rabbit 488 antibodies. The bone
pieces were ﬁnally examined with a confocal microscope (Nikon Eclipse Ti) under
FITC/TRITC/DIC signal channel. Images were analysed in imageJ. Analyse
Particles was used after thresholding to quantify positive signals and measure the
total area occupied by these particles.
CRABP2 expression on mouse cranium. NOD.CB17-Prkdcscid/J (NOD/SCID)
female mice aged 6–8 weeks were employed in this experiment. The mouse cra-
niums were collected from the last experiment. In this experiment, we also col-
lected the mouse craniums without any treatment as the control. The ex vivo
staining examination was followed by the traditional protocol. Brieﬂy, the mouse
craniums were cut into four pieces along the sutures producing one frontal, two
parietal and one occipital bone. Only parietal bones were used in this experiment.
Bone pieces were ﬁxed in 4% paraformadehyde for 30min, washed twice with PBS,
blocked with 2% BSA-0.01% Triton X-100 in PBS (BSA buffer) for 1 h and incu-
bated with primary antibodies (anti-CRABP2 antibody, ab74265, diluted 1:100 in
BSA buffer) overnight at 4 C. After washing with BSA buffer, bones were incu-
bated with secondary antibodies (goat anti-rabbit 488 antibodies, diluted 1:200 in
BSA buffer) for 2 h and then washed with BSA buffer. Nuclei were stained using
DAPI. The bone pieces were ﬁnally examined with a confocal microscope (Nikon
Eclipse Ti) under DAPI/FITC/DIC signal channel. Images were analysed in imageJ.
Analyse Particles was used after thresholding to quantify positive signals and
measure the total area occupied by these particles. Comparison between CD11b,
CD45 and CRABP2 positive areas was used as a proxy of the release of RA by NPs
and paracrine effect in the parietal bones of irradiated and non-irradiated mice.
All data generated or analysed during this study are included in this published
article (and its Supplementary Information ﬁles).
References
1. De Botton, S. et al. Incidence, clinical features, and outcome of all trans-retinoic
acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia.
The European APL Group. Blood 92, 2712–2718 (1998).
2. Warrell, R. P. Jr et al. Differentiation therapy of acute promyelocytic
leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324,
1385–1393 (1991).
3. Russo, D. et al. All-trans retinoic acid (ATRA) in patients with chronic myeloid
leukemia in the chronic phase. Leukemia 12, 449–454 (1998).
4. Si, J., Mueller, L. & Collins, S. J. CaMKII regulates retinoic acid receptor
transcriptional activity and the differentiation of myeloid leukemia cells. J. Clin.
Invest. 117, 1412–1421 (2007).
5. Montesinos, P. et al. Differentiation syndrome in patients with acute
promyelocytic leukemia treated with all-trans retinoic acid and anthracycline
chemotherapy: characteristics, outcome, and prognostic factors. Blood 113,
775–783 (2009).
6. Duan, C. W. et al. Leukemia propagating cells rebuild an evolving niche in
response to therapy. Cancer Cell 25, 778–793 (2014).
7. Timko, B. P., Dvir, T. & Kohane, D. S. Remotely triggerable drug delivery
systems. Adv. Mater. 22, 4925–4943 (2010).
8. Rwei, A. Y., Wang, W. & Kohane, D. S. Photoresponsive nanoparticles for drug
delivery. Nano Today 10, 451–467 (2015).
9. Bansal, A. & Zhang, Y. Photocontrolled nanoparticle delivery systems for
biomedical applications. Acc. Chem. Res. 47, 3052–3060 (2014).
10. Spring, B. Q. et al. A photoactivable multi-inhibitor nanoliposome for tumour
control and simultaneous inhibition of treatment escape pathways. Nat.
Nanotechnol. 14, 378–387 (2016).
11. Boussif, O. et al. A versatile vector for gene and oligonucleotide transfer into
cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92,
7297–7301 (1995).
12. Maia, J. et al. Controlling the neuronal differentiation of stem cells by the
intracellular delivery of retinoic acid-loaded nanoparticles. ACS Nano 5, 97–106
(2011).
13. Dvir, T., Banghart, M. R., Timko, B. P., Langer, R. & Kohane, D. S. Photo-
targeted nanoparticles. Nano Lett. 10, 250–254 (2010).
14. Tiyaboonchai, W., Woiszwillo, J. & Middaugh, C. R. Formulation and
characterization of amphotericin B-polyethylenimine-dextran sulfate
nanoparticles. J. Pharm. Sci. 90, 902–914 (2001).
15. Guidez, F. et al. Poor response to all-trans retinoic acid therapy in a t(11;17)
PLZF/RAR alpha patient. Leukemia 8, 312–317 (1994).
16. Licht, J. D. et al. Clinical and molecular characterization of a rare syndrome of
acute promyelocytic leukemia associated with translocation (11;17). Blood 85,
1083–1094 (1995).
17. Ruthardt, M. et al. Opposite effects of the acute promyelocytic leukemia PML-
retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins
on retinoic acid signalling. Mol. Cell. Biol. 17, 4859–4869 (1997).
18. Spicuglia, S. et al. Characterisation of genome-wide PLZF/RARA target genes.
PLoS ONE 6, e24176 (2011).
19. Bewersdorf, J., Bennett, B. T. & Knight, K. L. H2AX chromatin structures and
their response to DNA damage revealed by 4Pi microscopy. Proc. Natl Acad.
Sci. USA 103, 18137–18142 (2006).
20. Leith, C. P. et al. Acute myeloid leukemia in the elderly: assessment of
multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups
with remarkably distinct responses to standard chemotherapy. A Southwest
Oncology Group study. Blood 89, 3323–3329 (1997).
21. Meng, H. et al. Engineered design of mesoporous silica nanoparticles to deliver
doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer
cell line. ACS Nano 4, 4539–4550 (2010).
22. Drach, J., Lopez-Berestein, G., McQueen, T., Andreeff, M. & Mehta, K.
Induction of differentiation in myeloid leukemia cell lines and acute
promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res.
53, 2100–2104 (1993).
23. Tiwari, M. D., Mehra, S., Jadhav, S. & Bellare, J. R. All-trans retinoic acid loaded
block copolymer nanoparticles efﬁciently induce cellular differentiation in
HL-60 cells. Eur. J. Pharm. Sci. 44, 643–652 (2011).
24. Szuts, E. Z. & Harosi, F. I. Solubility of retinoids in water. Arch. Biochem.
Biophys. 287, 297–304 (1991).
25. Huang, P. X., Chandra, V. & Rastinejad, F. Retinoic acid actions through
mammalian nuclear receptors. Chem. Rev. 114, 233–254 (2014).
26. Douer, D. & Koefﬂer, H. P. Retinoic acid. Inhibition of the clonal growth of
human myeloid leukemia cells. J. Clin. Invest. 69, 277–283 (1982).
27. Liu, T. X. et al. Gene expression networks underlying retinoic acid-induced
differentiation of acute promyelocytic leukemia cells. Blood 96, 1496–1504
(2000).
28. Pitha-Rowe, I., Petty, W. J., Kitareewan, S. & Dmitrovsky, E. Retinoid target
genes in acute promyelocytic leukemia. Leukemia 17, 1723–1730 (2003).
29. Mao, M. et al. RIG-E, a human homolog of the murine Ly-6 family, is induced
by retinoic acid during the differentiation of acute promyelocytic leukemia cell.
Proc. Natl Acad. Sci. USA 93, 5910–5914 (1996).
30. Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA
delivery, intracellular trafﬁcking and endosomal escape. Nat. Biotechnol. 31,
638–646 (2013).
31. Sahay, G. et al. Efﬁciency of siRNA delivery by lipid nanoparticles is limited by
endocytic recycling. Nat. Biotechnol. 31, 653–658 (2013).
32. Li, J. et al. Near-infrared light-triggered release of small molecules for
controlled differentiation and long-term tracking of stem cells in vivo using
upconversion nanoparticles. Biomaterials 110, 1–10 (2016).
33. Lee, T. T. et al. Light-triggered in vivo activation of adhesive peptides regulates
cell adhesion, inﬂammation and vascularization of biomaterials. Nat. Mater. 14,
352–360 (2015).
34. Shanmugam, V., Selvakumar, S. & Yeh, C. S. Near-infrared light-responsive
nanomaterials in cancer therapeutics. Chem. Soc. Rev. 43, 6254–6287
(2014).
35. Wang, F. et al. Simultaneous phase and size control of upconversion
nanocrystals through lanthanide doping. Nature 463, 1061–1065 (2010).
36. Zong, H. et al. In vivo targeting of leukemia stem cells by directing
parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia 30,
1582–1586 (2016).
Acknowledgements
We acknowledge the use of the Laborato´rio de Bio-imagem de Alta Resoluc¸a˜o of the
Faculty of Medicine of University of Coimbra. The authors would like to thank the
ﬁnancial support of FEDER through the programme COMPETE and by Portuguese
funds through FCT (PTDC/CTM-NAN/120552/2010 and UID/NEU/04539/2013 to
R.P.N.), FCT (SFRH/BD/62419/2009 to C.B.; SFRH/BD/90964/2012 to E.Q.; POCI-01-
0145-FEDER-016390:CANCEL STEM to L.F.), EC (ERC project n 307384, ‘Nanotrigger’
to L.F.), MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Con-
solider OncoBIO SAF2014-57791-REDC to I.S.-G.) and Bloodwise and CRUK pro-
gramme grants to T.E.
Author contributions
C.B. contributed conceptually to the design of the nanoparticle system and together with
E.Q. carried out cell and animal studies, analysed data and wrote the manuscript; Y.C.
and D.H. contributed with animal studies and analysed data; A.M.-L., M.B.G.C. and
I.S.-G. contributed for animal studies; S.P. carried out cell characterization analyses; R.G.
and T.E. contributed for the cell studies; R.P.d.N. and L.F. contributed conceptually,
made measurements, analysed data and wrote the manuscript. All the authors have read
and approved the manuscript.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15204
12 NATURE COMMUNICATIONS | 8:15204 |DOI: 10.1038/ncomms15204 |www.nature.com/naturecommunications
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Boto, C. et al. Prolonged intracellular accumulation of
light-inducible nanoparticles in leukemia cells allows their remote activation.
Nat. Commun. 8, 15204 doi: 10.1038/ncomms15204 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15204 ARTICLE
NATURE COMMUNICATIONS | 8:15204 |DOI: 10.1038/ncomms15204 |www.nature.com/naturecommunications 13
